Qlife Holding AB (OSTO:QLIFE) Other Current Receivables: kr0.81 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:QLIFE Qlife Holding AB OSTO:QLIFE
18 GF Score
Price kr1.76
GF Value kr0.75
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Qlife Holding AB Other Current Receivables?

Qlife Holding AB OSTO:QLIFE -2.88% 18 Other Current Receivables is kr0.81 Mil as of Mar. 2026. GuruFocus rates OSTO:QLIFE with a GF Score™ of 18/100 and a GF Value™ of kr0.75 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Qlife Holding AB's Other Current Receivables for the quarter that ended in Mar. 2026 was kr0.81 Mil.

Qlife Holding AB's quarterly Other Current Receivables declined from Sep. 2025 (kr1.96 Mil) to Dec. 2025 (kr0.57 Mil) but then increased from Dec. 2025 (kr0.57 Mil) to Mar. 2026 (kr0.81 Mil).

Qlife Holding AB's annual Other Current Receivables declined from Dec. 2023 (kr2.95 Mil) to Dec. 2024 (kr0.23 Mil) but then increased from Dec. 2024 (kr0.23 Mil) to Dec. 2025 (kr0.57 Mil).

Qlife Holding AB Other Current Receivables Related Terms

Qlife Holding AB Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Qlife Holding AB's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qlife Holding AB Other Current Receivables Chart

Qlife Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 11.10 8.09 2.95 0.23 0.57

Qlife Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.59 1.96 0.57 0.81
OSTO:QLIFE
18GF Score
Qlife Holding AB OSTO:QLIFE
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qlife Holding AB Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of kr0.81 Mil mean?
Qlife Holding AB (OSTO:QLIFE) has a Other Current Receivables of kr0.81 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Qlife Holding AB and its competitors.
Is Qlife Holding AB's Other Current Receivables too high?
Qlife Holding AB's current Other Current Receivables is kr0.81 Mil. Overall, Qlife Holding AB has a GF Score™ of 18/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's Other Current Receivables compare to ABT and SYK?
Qlife Holding AB's Other Current Receivables of kr0.81 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Qlife Holding AB and its competitors. Qlife Holding AB's current Other Current Receivables is kr0.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.75, compared to a current price of kr1.76 — trading 134.1% above its estimated fair value. The current Other Current Receivables is kr0.81 Mil. Qlife Holding AB's overall GF Score™ is 18/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current Other Current Receivables is kr0.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued. The current stock price of kr1.76 is trading 134.1% above its estimated GF Value™ of kr0.75. GuruFocus considers Qlife Holding AB to be Significantly Overvalued.

Key valuation signals for OSTO:QLIFE:

  • Other Current Receivables: kr0.81 Mil
  • GF Value™: kr0.75 vs. price of kr1.76 (134.1% above fair value)
  • GF Score™: 18/100 with 9 warning signs

No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qlife Holding AB Business Description

Other Exchanges 4HG0:Germany
Address Nellikevagen 22, Goteborg, SWE, SE-412 63
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
18GF Score

Get the complete analysis for OSTO:QLIFE

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.76
Price
kr0.75
GF Value